News & Updates

Show Multimedia Only

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

07 Jan 2021 by

Physicians may often underestimate symptoms of pain, oedema, fatigue, and pruritus in patients undergoing radiotherapy for breast cancer, according to a study presented at SABCS 2020.

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

07 Jan 2021

Statins may protect the heart from chemo for breast cancer

07 Jan 2021 by

Women who received statins were less likely than those who did not to have ED* visits or hospitalizations for heart failure (HHF) following chemotherapy with anthracyclines for early breast cancer (EBC) — suggesting that statins may protect the heart against damage induced by chemotherapy, at least among older women.

Statins may protect the heart from chemo for breast cancer

07 Jan 2021

GI symptoms prevalent in hospitalized COVID-19 patients with cancer

07 Jan 2021

There is a high prevalence of acute gastrointestinal (GI) symptoms associated with coronavirus disease 2019 (COVID-19) in hospitalized cancer patients, which can occur as a presenting symptom without respiratory symptoms, reveals a recent study. In a small subset of patients, such symptoms are severe.

GI symptoms prevalent in hospitalized COVID-19 patients with cancer

07 Jan 2021

Which tool is best for screening interactions between herbal supplements, anticancer agents?

07 Jan 2021

The best available tool for detecting herb–drug interaction is Lexicomp, and the best free alternative is Medscape, suggests a study. However, the sensitivity and performance for detecting herb–drug interaction is far lower than for drug–drug interactions and quite poor overall.

Which tool is best for screening interactions between herbal supplements, anticancer agents?

07 Jan 2021

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

07 Jan 2021 by

The novel third-generation ALK* inhibitor lorlatinib outdid the first-generation inhibitor crizotinib as treatment for previously untreated advanced ALK+ non-small-cell lung cancer (NSCLC), according to the interim results of the CROWN trial.

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

07 Jan 2021

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

06 Jan 2021 by

Two years of maintenance olaparib reduces recurrence risk in women with newly diagnosed advanced ovarian cancer with BRCA mutation (BRCAm), according to long-term results of the SOLO1* trial.

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

06 Jan 2021

Blinatumomab continues to prevail over CT for ALL

06 Jan 2021 by

Two trials presented at ASH 2020 reflect the immuno-oncotherapeutic benefit of the BiTE®* molecule blinatumomab in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).

Blinatumomab continues to prevail over CT for ALL

06 Jan 2021

Acid reflux a gateway to multiple diseases

05 Jan 2021 by

Gastroesophageal reflux disease (GERD) may predispose patients to developing other diseases, as reported in a study. For the most part, it puts the whammy on chronic obstructive pulmonary disorder, doubling exacerbations, and raises the risk of oesophageal adenocarcinoma.

Acid reflux a gateway to multiple diseases

05 Jan 2021

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

05 Jan 2021

A reduction in pegfilgrastim doses among patients on myelosuppressive chemotherapy for breast cancer leads to a low incidence of neutropaenia-related events, including febrile and grade 3/4 neutropaenia, suggests a study.

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

05 Jan 2021

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

05 Jan 2021

New drug applications approved by US FDA as of 16 - 31 December 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

05 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

Physicians may underestimate symptoms in breast cancer patients undergoing radiotherapy

Statins may protect the heart from chemo for breast cancer

Statins may protect the heart from chemo for breast cancer

GI symptoms prevalent in hospitalized COVID-19 patients with cancer

GI symptoms prevalent in hospitalized COVID-19 patients with cancer

Which tool is best for screening interactions between herbal supplements, anticancer agents?

Which tool is best for screening interactions between herbal supplements, anticancer agents?

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

Blinatumomab continues to prevail over CT for ALL

Blinatumomab continues to prevail over CT for ALL

Acid reflux a gateway to multiple diseases

Acid reflux a gateway to multiple diseases

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

Reduced pegfilgrastim dose lowers neutropaenia-related events in breast cancer patients

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)